In short
NM26-2198 (also known as JNJ-95475939) is an investigational bispecific antibody being studied for the treatment of moderate to severe atopic dermatitis. It is a protein-based medicine given by subcutaneous injection and has no marketing authorisation. One Phase 2b trial, completed with 240 participants, evaluated its efficacy and safety compared with placebo and dupilumab.
Key points
- NM26-2198 is an investigational bispecific antibody for moderate to severe atopic dermatitis.
- The only registered trial is a Phase 2b study with 240 participants.
- The trial measured EASI 75 at Week 12 as its primary endpoint.
- The study compared NM26-2198 with placebo and dupilumab.
- The trial is completed, but results have not been described in these records.
- NM26-2198 is given as a solution for injection under the skin.
What is NM26-2198?
NM26-2198, also known as JNJ-95475939, is an investigational bispecific, tetravalent antibody. It is a protein-based substance developed for the treatment of moderate to severe atopic dermatitis, a chronic inflammatory skin condition. The substance has no marketing authorisation in the product records, meaning it is still being studied in clinical trials and is not available as a licensed medicine. The authorisation holder listed in the trial record is Janssen-Cilag International N.V.
How does NM26-2198 work?
NM26-2198 is designed as a bispecific antibody, meaning it can bind to two different targets at the same time. According to a review of emerging therapies, it targets both inflammatory and pruritogenic (itch-related) pathways involved in atopic dermatitis. Most currently approved biologic treatments for atopic dermatitis target only one molecule, whereas multi-specific antibodies such as NM26-2198 are intended to block several pathways at once. This approach is being explored because many patients treated with single-target biologics still do not achieve clear or almost clear skin. The review lists NM26-2198 among a growing group of bispecific and trispecific antibodies being developed for atopic dermatitis.
Which conditions is it studied for?
- Moderate to severe atopic dermatitis — a long-lasting inflammatory skin disease that causes intense itching and skin lesions. The Phase 2b trial enrolled participants with this severity of disease.
How is NM26-2198 given?
NM26-2198 is formulated as a solution for injection and is given by subcutaneous use, meaning it is injected under the skin. The trial compared NM26-2198 with dupilumab (Dupixent), which was also given subcutaneously, and with a placebo version of NM26-2198.
What do the clinical trials show?
One Phase 2b trial of NM26-2198 is registered. It was a multicentre, randomised, double-blind study that included 240 participants with moderate to severe atopic dermatitis. The trial was designed to evaluate the efficacy and safety of different doses of NM26-2198 compared with placebo and with dupilumab. The primary outcome was EASI 75 at Week 12, which measures the proportion of participants achieving at least a 75% improvement in the Eczema Area and Severity Index (EASI) from the start of the study. The trial is listed as completed, but the registry records do not include the results.
What side effects are known?
The available sources do not provide specific information on side effects observed with NM26-2198. No safety data from the completed trial or from other publications are described in the records provided.